Virginia G. Kaklamani, MD, DSc

Articles

Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer

December 11th 2024

Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer.

Dr Kaklamani on the Role of Adjuvant Ribociclib in Early-Stage HR+/HER2– Breast Cancer

September 24th 2024

Virginia Kaklamani, MD, discusses the optimal role for adjuvant ribociclib alongside endocrine therapy in early-stage HR+/HER2– breast cancer.

Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer

July 29th 2024

In their concluding remarks, Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, summarize their key insights and perspectives on the management of HR+ breast cancer.

Future Directions and Unmet Needs in HR+ Breast Cancer

July 29th 2024

The key opinion leaders discuss the current unmet needs in the management of HR+/HER2- metastatic breast cancer and explore potential future directions and strategies that may lead to improved patient outcomes.

Combinations and Treatment Sequence Strategies in Breast Cancer

July 22nd 2024

In their discussion, the key opinion leaders explore the potential of combination therapies in HR+/HER2- metastatic breast cancer, with a specific focus on the ELECTRA study, which investigated the combination of elacestrant and abemaciclib.

PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors

July 22nd 2024

The expert panel examines the subgroup data from the postMONARCH study, focusing on patients with ESR1 and PIK3CA mutations, and emphasizes the important role of CDK4/6 inhibitors in the treatment of these specific patient populations with HR+/HER2- metastatic breast cancer.

PIK3CA Mutations and Delivering PI3K Inhibitors

July 15th 2024

In their discussion, the key opinion leaders explore the significance of PIK3CA mutations in HR+/HER2- metastatic breast cancer and review the findings from two pivotal clinical trials, SOLAR-1 and CAPItello-291, which investigated the efficacy of targeted therapies in patients harboring these mutations.

Case Presentation 2: Co-mutations in ESR1 and PIK3CA

July 15th 2024

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, discuss the clinical presentation and management of a 64-year-old postmenopausal female with a history of rheumatoid arthritis who was diagnosed with stage IV, grade 3, invasive ductal carcinoma in her left breast, taking into account her comorbidities and the advanced stage of her breast cancer.

Evolving Best Practices for ESR1 Testing

July 8th 2024

The breast cancer experts share their clinical experiences and strategies regarding the optimal timing for testing ESR1 mutations in patients with HR+/HER2- metastatic breast cancer, elaborating on how the specific points in the treatment journey at which they recommend testing influence their subsequent treatment decisions and overall approach to patient management.

EMERALD Study Design and Results for Elacestrant

July 8th 2024

Key opinion leaders examine the EMERALD trial, which evaluates the efficacy of elacestrant in patients with HR+ HER2- metastatic breast cancer, focusing on the subgroup analysis of patients with visceral metastases, and explore how the trial's design and results have influenced their clinical practice.

Case Presentation 1: PIK3CA Mutation With ESR1 Mutations

July 1st 2024

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, present a patient case involving a 54-year-old postmenopausal woman diagnosed with a 2.1cm estrogen receptor positive (ER+), HER2 negative breast cancer, and discuss the clinical implications and management strategies for this specific patient scenario.

Dynamics of ESR1 Alterations and Serial Liquid Biopsies

July 1st 2024

In their discussion, medical experts in the field of breast cancer explore the role of liquid biopsies and compare the significance of ESR1 mutations to other biomarkers, such as PIK3CA, in terms of their driver versus passenger status in the context of HR+/HER2- breast cancer.

Evolution of Testing Strategies for ESR1

June 25th 2024

The key opinion leaders (KOLs) review the current testing methods for detecting ESR1 mutations and explore the existing strategies employed to overcome or delay the development of these mutations and the associated endocrine resistance in patients with HR+/HER2- metastatic breast cancer.

Prevalence and Testing Strategies for ESR1

June 25th 2024

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, explore the clinical significance of *ESR1* mutations in HR+/HER2- metastatic breast cancer patients, including their impact on disease prognosis, treatment outcomes, and the increasing prevalence of these mutations with each line of endocrine therapy, ultimately informing their therapeutic approach.

The Future of HER2+ Breast Cancer Treatment

August 24th 2023

Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.

Patient Profile 3: Metastatic HER2+ BC

August 17th 2023

Dr Kaklamani presents a profile of a patient with HER2+ breast cancer and liver metastases who had disease progression after first-line chemotherapy and a solitary new brain metastasis after second-line T-DM1.

Patient Profile 2: Early Stage HER2+/HR- BC

August 17th 2023

Melinda L. Telli, MD, presents a profile of a patient with early stage breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery, whose tumor was initially HER2+ but became triple-negative after treatment.

Patient Profile 1: Early Stage HER2+/HR+ BC

August 10th 2023

Virginia G. Kaklamani, MD, DSc, presents a patient profile of early stage HER2+ breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery.

Typical Approaches for Treatment Selection in the Third Line and Beyond

August 10th 2023

Experts share their go-to regimens in the third-line and higher setting of HER2+ metastatic breast cancer, and touch on the factors that support their decision-making.

HER2+ mBC: Emerging Agents in the Third-Line and Higher Setting

August 3rd 2023

Debu Tripathy, MD, discusses novel therapies being developed for later-line treatment of HER2+ mBC.